Zwangsstörungen

Kernaussagen

• Die Zwangsstörung ist eine schwere, meist chronische psychische Erkrankung, die häufig vor anderen Personen, insbesondere auch vor Ärzten und Psychotherapeuten, verheimlicht wird.

• Zwangsstörungen weisen eine hohe Komorbidität mit anderen psychischen Erkrankungen auf, insbesondere mit depressiven Störungen, Angststörungen, Persönlichkeitsstörungen und Essstörungen.

• An effektiven Behandlungsstrategien steht heute die kognitive Verhaltenstherapie mit Reizkonfrontation (Exposition) und Reaktionsmanagement sowie selektive Serotonin-Wiederaufnahmehemmer zur Verfügung. Die Kombination beider Verfahren kann zu Responderraten von 80 bis 90 % der Patienten führen. Bei Therapieresistenz ist die Wirksamkeit atypischer Neuroleptika erwiesen.

• Behandlungserfolg bzw. Response bedeutet bei Zwangsstörungen meist eine deutliche Symptomreduktion, äußerst selten jedoch eine Remission.

• Die Versorgungssituation für Patienten, die an Zwangsstörungen erkrankt sind, ist noch sehr unzureichend. Bei vielen Patienten werden unwirksame Fehlbehandlungen durchgeführt, bevor spezifische, evidenzbasierte Therapien zur Anwendung kommen.

Publication History

Publication Date:
16 April 2007 (online)

• Literatur

• Kessler R, McGonagle K, Zhao S. Lifetime and 12-month prevalence of DSM-II-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.. Arch Gen Psych 1994; 51: 8-19
• Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder.. Arch Gen Psychiat 1999; 56: 121-127
• Stengler-Wenzke K, Beck M, Holzinger A, Angermeyer MC. Stigmatisierungserfahrungen von Patienten mit Zwangserkrankungen.. Fortschritte der Neurologie - Psychiatrie 2004; 72: 7-13
• Winkelmann G, Rasche H, Hohagen F. Zwangsstörungen: Komorbidität und Implikationen für die Behandlung.. Praxis der Rehabilitation und Verhaltenstherapie 1994; 25: 32-40
• Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder.. Psychiatric Clinics of North America 1992; 15: 743-758
• Nestadt G, Samuels J, Riddle MA. et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study.. Psychological Medicine 2001; 31: 481-7
• Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.. Arch Gen Psychiatry 1998; 45: 977-86
• Poyurovsky M, Weizmann A, Weizmann R. Obsessive-Compusive Disorder in Schizophrenia. Clinical Characteristics and Treatment.. CNS Drugs 2004; 18: 989-1010
• Petter T, Richter MA, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics.. J Clin Psychiatry 1998; 59: 45-49
• Mancebo MC, Eisen JL, Grant JE, Rasmussen SA. Obsessive compulsive personality disorder and obsessive compulsive disorder: clinical characteristics, diagnostic difficulties, and treatment.. Annales of Clinical Psychiatry 2005; 17: 197-204
• Dale RC, Heyman I, Giovannoni G, Church AW. Incidence of anti-brain antibodies in children with obsessive-compulsive disorder.. Br J Psychiatry 2005; 187: 314-319
• Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder.. Psychiatry Res 2004; 15: 69-79
• Rauch SL. Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders.. Neurosurg Clin N Am 2003; 14: 213-23
• Rauch SL, Jenike MA, Alpert NM. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography.. Arch Gen Psychiatry 1994; 51: 62-70
• Billet EA, Richter MA, Kennedy JL. Genetics of obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA Obsessive-Compulsive Disorder. Theory, research, and treatment.. New York, London, The Guilford Press: 1998: 181-206
• Kuelz AK, Hohagen F, Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review.. Biological Psychology 2004; 65: 185-236
• Kuelz AK, Riemann D, Halsband U. et al. Neuropsychological impairment in OCD - improvement over the course of cognitive behavioral treatment.. Journal of Clinical and Experimental Neuropsychology 2006; 28: 1-15
• Salkovskis WM, Warwick HM. Cognitive therapy of obsessive - compulsive disorder. In: Paris C, Blackburn IM, Perris H Cognitive Psychotherapy - Theory and Practice.. Berlin,Springer: 1988
• Abramowitz JS. The Psychological Treatment of Obsessive Compulsive Disorder.. Can J Psychiatry 2006; 51: 407-416
• Neziroglu F, Henricksen J, Yaryura-Tobias JA. Psychotherapy of obsessive-compulsive disorder and spectrum: established facts and advances, 1995 - 2005.. Psychiatric Clinics of North America 2006; 29: 585-604
• Mataix-Cols D, Marks IM. Self-help with minimal therapist contact for obsessive-compulsive disorder: a review.. European Psychiatry 2006; 21: 75-80
• Kordon A, Kahl KG, Broocks A, Voderholzer U, Rasche-Räuchle H, Hohagen F. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up.. European Archives of Psychiatry & Clinical Neuroscience Feb 2005; 255: 48-50
• Rufer M, Hand I, Alsleben H. et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.. Eur Arch Psych Clin Neurosci 2005; 255 (2): 121-128
• Blier P, Habib R, Flament MF. Pharmacotherapies in the Management of Obsessive-Compulsive Disorder.. Can J Psychiatry 2006; 51: 417-430
• Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.. Psychiatric Clinics of North America 2006; 29: 553-84
• Bergqvist PB, Bouchard C, Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder.. Biological Psychiatry 1999; 45: 164-74
• Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.. J Clin Psychopharmacol 2002; 22: 309-17
• Denys D, Megen HJ van, Wee N van der  , Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.. Journal of Clinical Psychiatry 2004; 65: 37-43
• Foa EB, Liebowitz MR, Kozak MJ. et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramin, and their Combination in the Treatment of Obsessive-Compulsive Disorder.. Am J Psychiatry 2005; 162: 151-161
• Hohagen F, Winkelmann G, Rasche RH. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.. Br J Psychiatry 1998; Suppl 35: 71-78
• Geller DA, Biederman J, Stewart SE. et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder.. Am J Psychiatry 2003; 160: 1919-1928
• Hoehn-Saric SR, Ninan P, Black DW. et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.. Arch Gen Psychiatry 2000; 57: 76-82
• Greenberg BD, Malone DA, Friehs GM. et al. Three-Year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder.. Neuropsychopharmacology 2006; 31: 2384-2393
• March JS, Frances A, Kahn DA, Carpenter D. The Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder.. J Clin Psychiatry 1997; 58 (suppl 4): 0
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders.. World J Biol Psychiatry 2002; 3 (4): 171-199